Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

(750) (2,151) Research and development expenses. (74,281) (48,278) Administrative and selling expenses (11,358) (11,322) Other income 3,814 3,933 Operating loss (79,213) (37,198) Net financial income 5,458 5,183 Loss before income tax (73,755) (32,015) Income tax expense (132) (129) Loss for the period (73,887) (32,144) Attributable to: - Equity holders of the Company (73,887) (32,144) - minority interests - - Earnings per share for profit attributable to equity holders of the Company (1.56) (0.69) Diluted (1.56) (0.69) CONSOLIDATED BALANCE SHEET December 31, 2008 December 31, 2007 (in thousands of EUR) ASSETS Non current assets Property, plant, & 3,429 2,720 equipment Intangible 835 464 assets Financial instruments 4,858 14,402 Government subsidies receivable - 5,264 Other financial assets 201 186 Deferred income tax assets 21 10 Total non-current 9,344 23,046 assets Current assets Financial assets 396 - Trade receivables
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... may seem obvious that dunking relatively spherical objects in ... will result in an array of completely encapsulated berries. ... have similarly dunked their wares in protective coatings in ... chemical interactions with solvents. Unfortunately, reactions in the ...
... Beta-Pro LLC, announced today that it has expanded ... drug discovery and research institutes in the $2 ... now manages extensive laboratory facilities in the University ... "Beta-Pro has already established a foothold ...
... US Oncology, Inc., the nation,s leading integrated oncology ... patient in a Phase I clinical trial through its ... trials present special challenges, including increased safety concerns, higher ... some first-in-human trials, making Phase I trials more difficult ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... When in an environment similar to that in which ... actions or dynamics different than those they exhibit when ... often studied, said researchers at Baylor College of Medicine ... journal Structure. , In a study using electron ...
... got its feathers in the right place is not a ... causes can stack up into complicated results. For a chicken, ... stripes. For biologists at the University of Southern California and ... question of patterning. , To understand patterning on ...
... of combating diseases related to the immune system, including cancer ... The study, funded by the Wellcome Trust, appears online in ... body to fight infection. Scientists previously identified two types of ... which attack infected cells, and "regulatory T cells", which suppress ...
Cached Biology News:Embryonic patterning makes the feathers fly 2T for two: Scientists show how immune system chooses best way to fight infection 2
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
... CUL-3 is a member of the family of human ... homologous to the S. cerevisiae cdc53 gene. Cullin-3 is ... It forms a tight complex with cyclin E and ... by protesomes. Cyclin E is an activator of cdk2, ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: